Study Looks at Alcohol Intake, Mortality Link in Steatotic Liver Disease
By Elana Gotkine HealthDay Reporter
THURSDAY, Dec. 14, 2023 -- For individuals with steatotic liver disease (SLD) at low risk for advanced fibrosis, there is a nonlinear association between alcohol consumption and mortality, with increased risk at or above consumption of 7.4 g/day, according to a research letter published online Dec. 14 in JAMA Network Open.
Yee Hui Yeo, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues examined the dose-dependent association of alcohol use with progression of SLD using a noninvasive method based on data from the U.S. National Health and Nutrition Examination Survey III (1988 to 1994) database, followed through Dec. 31, 2019.
The researchers found that 20.8 percent of the 2,834 individuals with SLD had intermediate or high risk of advanced fibrosis, with male predominance and higher prevalence of metabolic disorders. Individuals at intermediate or high risk of advanced fibrosis had a mortality rate of 4,342 per 100,000 persons during 66,299 person years of follow-up, compared with 1,099 per 100,000 persons in the low-risk group. A nonlinear association between alcohol consumption and mortality was seen in the low-risk group after adjustment for demographic characteristics and metabolic variables. At a 7.4-g daily intake, mortality risk exceeded an adjusted hazard ratio of 1.00. In the intermediate- or high-risk groups, a linear association was observed between daily alcohol consumption and increased mortality risk.
"The finding aligns with previous research indicating higher risk of fibrosis progression among moderate drinkers," the authors write. "Individuals with SLD should be advised to maintain regular health monitoring and lifestyle management."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
MRE-Liver Stiffness Measure Better for Varices in NAFLD Cirrhosis
WEDNESDAY, May 8, 2024 -- For patients with obesity and nonalcoholic fatty liver disease (NAFLD) compensated cirrhosis (CC), liver stiffness measurement (LSM) by magnetic...
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
TUESDAY, April 30, 2024 -- For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter...
NASH Resolution Increased, Improvement of Fibrosis Seen With Resmetirom
THURSDAY, Feb. 8, 2024 -- For patients with nonalcoholic steatohepatitis (NASH) and fibrosis stage F1B, F2, or F3, 80- and 100-mg resmetirom is better than placebo, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.